Effect of ouabain on the anterograde effective refractory period of accessory atrioventricular connections in children.
The anterograde effective refractory period of the accessory connection was determined before and after the administration of ouabain (0.015 mg/kg intravenously) during electrophysiologic studies in 21 patients with Wolff-Parkinson-White syndrome. The mean age (+/- standard deviation) was 10 +/- 2 years (range 1 month to 31 years). Each patient had stopped taking all cardiac drugs for more than 36 hours. Determination of the anterograde effective refractory period of the accessory connection was made using the atrial extrastimulus technique. A change in the anterograde refractory period of the accessory connection was defined as an increase or decrease of greater than 10 ms from the value before ouabain administration. The post-ouabain anterograde effective refractory period of the accessory connection increased in 2 (9%) of the 21 patients, decreased in 9 (43%) and was unchanged in 10 (48%). This study demonstrated a decrease in the anterograde effective refractory period of the accessory connection of 43% of patients with Wolff-Parkinson-White syndrome after the administration of ouabain.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004594:Electrophysiology / Q000187:drug effects; D005260:Female; D006321:Heart / Q000502:physiology; D006325:Heart Atria / Q000033:anatomy & histology; D006329:Heart Conduction System / Q000187:drug effects* / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects*; D006346:Heart Septum / Q000033:anatomy & histology; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D010042:Ouabain / Q000008:administration & dosage*; D013610:Tachycardia / Q000139:chemically induced / Q000188:drug therapy; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy
D004071:Digitalis Glycosides; D010042:Ouabain